Loading organizations...
§ Venture Capital · Emeryville, CA, USA
Develops therapeutic antibody discovery platform using chickens for drug development, focused on intractable human targets.
Crystal Bioscience Inc. develops therapeutic antibody discovery solutions, providing a unique platform for diverse antibody panels. The company leverages chicken immunology to produce fully human antibodies. These antibodies offer cross-species reactivity, removing the need for surrogate antibodies in preclinical studies and enhancing early drug development.
Established in 2008, Crystal Bioscience was founded by Robert Etches, Marie-Cecile Van de Lavoir, and Bill Harriman. Their core insight focused on avian biology's potential to address challenges in antibody generation. Dr. Etches, a recognized geneticist, was instrumental in establishing the scientific foundation for the company's proprietary discovery engine.
Crystal Bioscience supports pharmaceutical and biotechnology companies requiring robust antibody candidates for novel therapeutics. Its mission is to advance its platform, facilitating rapid identification and development of potent biological drugs, thereby expanding innovative treatments for human diseases.
CrystalBioScience has 1 tracked investment across 1 company. The latest tracked deal is $11.0M Series D in OncoPep in December 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 9, 2021 | OncoPep | $11.0M Series D | Kukje Pharma, Tera Science | SX Company |